About This Guide
This comprehensive guide was shaped by the academic inspiration drawn from the lecture of Assist. Prof. Dr. Waleed Al-Ansari / Critical Care Medicine, whose teaching and pathophysiologic insights are respectfully integrated throughout this work.
This guide covers updated Berlin/PALICC definitions, detailed pathophysiology, differentiation from mimics, modern ICU management including prone positioning and ECMO, resource-limited strategies, special populations, and expert-level MCQs.
01
Introduction to ARDS
Acute Respiratory Distress Syndrome (ARDS) is a clinically defined, life-threatening form of acute, non-cardiogenic respiratory failure that occurs in response to a wide variety of direct and indirect lung injuries.
Defining Characteristics
- Acute onset (within 1 week of a known clinical insult)
- Bilateral pulmonary infiltrates on chest imaging (not fully explained by effusion, collapse, or nodules)
- Hypoxemia, defined by a PaO₂/FiO₂ ratio ≤300 mmHg while on PEEP ≥5 cmH₂O
- Exclusion of cardiac failure or fluid overload as the primary cause
Key Molecular Drivers
🔹 ICAM-1 — Promotes firm neutrophil adhesion to endothelium → upregulated during inflammation → amplifies lung injury through proteases and ROS.
🔹 ELAM-1 (E-selectin) — Enables initial neutrophil rolling on activated endothelium → guides neutrophils toward full adhesion via ICAM-1.
🔸 Hyaline Membranes — Formed by fibrin + necrotic epithelial debris → appear by Day 2–3 → histological hallmark of DAD.
🔻 Ineffective HPV — Normally diverts blood from poorly ventilated alveoli. In ARDS this reflex is blunted → perfusion of non-aerated lung zones → refractory hypoxemia.
📊 Epidemiology
| Metric | Value |
|---|---|
| Global ICU incidence | ~10% |
| ARDS among ventilated patients | ~23% |
| Mortality — Mild | ~27% |
| Mortality — Moderate | ~32% |
| Mortality — Severe | ~45% |
| Resource-limited countries | May exceed 60% |
Historical Context
- 🗓️ 1967: ARDS first described by Dr. Ashbaugh et al. as dyspnea, cyanosis, bilateral infiltrates, and poor response to oxygen.
- Initially called "Adult" Respiratory Distress Syndrome to distinguish from neonatal RDS.
- Name evolved to include all age groups → Acute Respiratory Distress Syndrome.
02
Pathophysiology of ARDS
Three Overlapping Phases
Phase 1
Exudative
Days 0–7
Phase 2
Proliferative
Days 7–21
Phase 3
Fibrotic
After Day 21
📍 Phase 1: Exudative (Day 0–7)
Pathology: Injury to alveolar epithelium and capillary endothelium. Massive cytokine release (TNF-α, IL-1β, IL-6). Neutrophil activation → free radicals + proteases → further damage. Leakage of protein-rich fluid into alveoli → pulmonary edema.
Structural changes: Loss of surfactant → alveolar collapse. Formation of hyaline membranes. Impaired gas exchange, decreased compliance.
Clinical: Rapid-onset dyspnea, refractory hypoxemia, bilateral infiltrates on CXR/CT, normal cardiac function.
📍 Phase 2: Proliferative (Day 7–21)
Type II pneumocytes proliferate → attempt to restore alveolar lining. Macrophages clear cellular debris. Organization of alveolar exudates begins. Fibroblast recruitment → risk of lung fibrosis.
📍 Phase 3: Fibrotic (After Day 21)
Collagen deposition, thickened alveolar walls. Fixed architectural damage → reduced lung compliance. May lead to chronic restrictive lung disease in survivors. Long-term: persistent dyspnea, reduced DLCO, ICU-acquired weakness.
| Phase | Key Features |
|---|---|
| Exudative | Capillary leak, alveolar edema, inflammatory infiltration, ↓ surfactant |
| Proliferative | Repair begins, organization of exudate, type II pneumocyte proliferation |
| Fibrotic | Lung fibrosis, permanent architecture damage, reduced compliance |
03
Causes & Risk Factors
🔹 Direct (Pulmonary) Causes
| Cause | Mechanism |
|---|---|
| Pneumonia (bacterial/viral) | Inflammation and infection destroy alveolar membrane |
| Aspiration of gastric contents | Acid injury + particulate blockage + infection |
| Pulmonary contusion | Trauma-induced alveolar bleeding and edema |
| Near-drowning | Water aspiration → surfactant washout + chemical irritation |
| Inhalation injury | Direct alveolar injury from heat and chemicals |
| COVID-19 ARDS | Prolonged hypoxemia, diffuse CT changes, microvascular thrombosis |
🔸 Indirect (Extrapulmonary) Causes
| Cause | Mechanism |
|---|---|
| Sepsis (non-pulmonary) | Cytokine storm, endothelial dysfunction, increased permeability |
| Pancreatitis | Systemic inflammation → lung injury via cytokines |
| Trauma or fractures | Fat embolism, hemorrhagic shock → lung microvascular damage |
| TRALI | Neutrophil activation due to donor anti-leukocyte antibodies |
| Burns | Systemic inflammation and inhalation component |
| Cardiopulmonary bypass | Contact activation of leukocytes + cytokine surge |
🔁 ARDS Mimics — Always Rule Out
| Condition | Why It Mimics ARDS |
|---|---|
| Cardiogenic pulmonary edema | Bilateral infiltrates, crackles, hypoxia — use BNP, echo to differentiate |
| Interstitial lung disease (acute) | Diffuse infiltrates and dyspnea |
| Pulmonary hemorrhage syndromes | Hemoptysis, infiltrates, often with systemic illness |
| Acute eosinophilic pneumonia | Rapid hypoxia, high eosinophil count, similar imaging |
🚩 Clinical Pearls
- In trauma or pancreatitis, ARDS may be silent at first, then worsen rapidly within 48–72 hours.
- Time to diagnosis is critical — early ARDS management = improved survival.
- Always treat the root cause first — antibiotics in sepsis, drainage in pancreatitis.
04
Diagnosis & the Berlin Criteria
| Component | Berlin Criteria (2012) |
|---|---|
| 1️⃣ Timing | Within 1 week of a known clinical insult OR new/worsening respiratory symptoms |
| 2️⃣ Imaging | Bilateral opacities on chest X-ray or CT — not fully explained by effusion, collapse, or nodules |
| 3️⃣ Origin of Edema | Respiratory failure not fully explained by cardiac failure or fluid overload |
| ➤ Mild ARDS | PaO₂/FiO₂ = 200–300 mmHg (on PEEP ≥5 cmH₂O) |
| ➤ Moderate ARDS | PaO₂/FiO₂ = 100–200 mmHg |
| ➤ Severe ARDS | PaO₂/FiO₂ ≤100 mmHg |
🧮 How to Calculate the P/F Ratio
Formula
P/F Ratio = PaO₂ (mmHg) ÷ FiO₂ (as a decimal)
- Example 1 — Mild ARDS: PaO₂ = 85 mmHg, FiO₂ = 0.40 → P/F = 85 ÷ 0.40 = 212.5
- Example 2 — Moderate ARDS: PaO₂ = 90 mmHg, FiO₂ = 0.60 → P/F = 90 ÷ 0.60 = 150
- Example 3 — Severe ARDS: PaO₂ = 65 mmHg, FiO₂ = 0.80 → P/F = 65 ÷ 0.80 = 81.25 🚨
- Example 4 — Normal: PaO₂ = 95 mmHg, FiO₂ = 0.21 → P/F = 95 ÷ 0.21 = 452
⚠️ ARDS vs Cardiogenic Pulmonary Edema
| Feature | ARDS | Cardiogenic Edema |
|---|---|---|
| Onset | Acute (hours–days) | Acute or chronic exacerbation |
| LV function (Echo) | Often preserved | Usually reduced |
| BNP | Normal or mildly ↑ | Markedly ↑ |
| PCWP (if monitored) | < 18 mmHg | > 18 mmHg |
| BAL | Neutrophils, proteinaceous fluid | Clear transudate |
05
Investigations & Workup
Goals
- Confirm the diagnosis using ABG and imaging
- Identify and treat the underlying cause (e.g., sepsis, trauma, aspiration)
- Exclude mimics (e.g., heart failure, interstitial lung disease)
- Monitor severity and progression
- Guide management (e.g., fluids, ventilation, ECMO)
Key Investigations
| Investigation | Role |
|---|---|
| ABG (PaO₂, PaCO₂, pH, Lactate) | P/F ratio calculation, acid-base status, hypoperfusion |
| BNP / NT-proBNP | Elevated in heart failure; low in ARDS → exclude cardiogenic cause |
| Echocardiography | Assess LV function, RV strain, IVC dynamics |
| Chest X-ray / CT | Bilateral opacities, ground-glass, dependent consolidation |
| Blood cultures + PCR | Detect bacteremia, viral etiology (COVID-19, Influenza) |
| Procalcitonin, CRP | Assess systemic inflammation, guide antibiotics |
| BAL (Bronchoalveolar Lavage) | Infection, hemorrhage, eosinophilia — when diagnosis unclear |
| D-dimer, Coagulation panel | Rule out PE, assess DIC |
06
Management in Developed ICU Settings
1️⃣ Lung-Protective Ventilation (LPV) — The Core
Based on the ARMA trial (NEJM 2000):
| Setting | Target |
|---|---|
| Tidal Volume (Vt) | 4–6 mL/kg predicted body weight |
| Plateau Pressure (Pplat) | ≤30 cm H₂O |
| Driving Pressure (ΔP) | ≤15 cm H₂O (Pplat − PEEP) |
| RR | Allow permissive hypercapnia if pH > 7.15 |
ARDSnet PEEP/FiO₂ Tables
🔵 Low PEEP / High FiO₂ Strategy
| FiO₂ | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|
| PEEP | 5 | 5–8 | 8–10 | 10 | 10–12 | 12 | 14 | 14–16 |
🔴 High PEEP / Lower FiO₂ Strategy
| FiO₂ | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|
| PEEP | 10 | 12 | 14 | 16 | 16–18 | 18–20 | 20–22 | 22–24 |
2️⃣ Prone Positioning — Game-Changer
Proven to improve oxygenation and survival in moderate-severe ARDS (P/F < 150)
Start early, within first 36 hours
Duration: 16 hours/day (PROSEVA trial)
💡 Improves V/Q matching, drainage of secretions, and reduces ventral overdistension.
Start early, within first 36 hours
Duration: 16 hours/day (PROSEVA trial)
💡 Improves V/Q matching, drainage of secretions, and reduces ventral overdistension.
3️⃣ Other Key Interventions
| Strategy | Details |
|---|---|
| Neuromuscular Blockade | Cisatracurium infusion ≤48h in severe ARDS (ACURASYS trial). Monitor for ICU-acquired weakness. |
| Conservative Fluid Strategy | Dry approach after shock resolution. Maintain negative fluid balance. Avoid overload → worsens pulmonary edema. |
| ECMO (VV) | Severe ARDS, refractory hypoxemia — EOLIA trial. Involve ECMO centers early. |
| Inhaled vasodilators | iNO, prostacyclin — temporary O₂ improvement, no mortality benefit. |
| Daily awakening + SBT | Prevents prolonged ventilation |
🧠 Clinical Pearls:
• Driving pressure is emerging as a stronger predictor of outcome than plateau pressure.
• Early proning saves lives — don't delay.
• If PaO₂ <55 on 100% FiO₂ + PEEP ≥10 → consider ECMO center referral.
• Driving pressure is emerging as a stronger predictor of outcome than plateau pressure.
• Early proning saves lives — don't delay.
• If PaO₂ <55 on 100% FiO₂ + PEEP ≥10 → consider ECMO center referral.
07
Management in Resource-Limited Settings
1️⃣ Oxygen Delivery Without Ventilators
| Device | FiO₂ Range | Notes |
|---|---|---|
| Nasal Cannula | 24–44% | Max ~6 L/min |
| Simple Face Mask | 40–60% | 6–10 L/min |
| Non-Rebreather Mask (NRB) | ~80–90% | Best for pre-intubation or bridging hypoxemia |
| CPAP (if available) | Up to 100% | Via face mask + PEEP valve |
| HFNC (High Flow Nasal Cannula) | Up to 100% | Needs blender, humidifier, flow ≥40 L/min |
2️⃣ Safe Ventilation Without Full ICU Monitoring
| Setting | Target |
|---|---|
| Tidal volume | 4–6 mL/kg PBW — manually calculated |
| PEEP | Start at 5 cmH₂O; titrate slowly based on SpO₂ |
| RR | 20–30/min; adjust for permissive hypercapnia |
| FiO₂ | Start at 100%, wean cautiously |
| Plateau pressure | Aim <30 cmH₂O (if measurable) |
3️⃣ Awake Proning — Cost-Free, Evidence-Based
For non-intubated patients: rotate between prone, left lateral, right lateral, and upright — 1–2 hours per position. Watch SpO₂ — many patients improve 5–10% within 10 minutes. Scalable with minimal resources.
4️⃣ Fluid Management Without CVP or Ultrasound
- Use clinical signs: JVP, urine output, tachypnea, mental status
- In shock: Bolus 10–20 mL/kg, reassess every 15 minutes
- No shock: Avoid liberal fluids, daily weight + auscultation tracking
- Use diuretics when lungs sound "wet" and perfusion is stable
🧠 Minimalist ICU Pearls
- 🧼 Minimize infections: hand hygiene, head-of-bed elevation
- 🚫 Avoid excessive sedation: awakening trials promote earlier extubation
- 🔄 Repurpose devices: bubble CPAP, PEEP valves on manual resuscitators
- Daily checklist: fluid status, feeding, SpO₂, mobility, pressure injuries
08
Special Populations
👶 1. Pediatric ARDS (PARDS)
Based on PALICC criteria. Uses Oxygenation Index (OI) instead of PaO₂/FiO₂:
OI = (FiO₂ × MAP × 100) ÷ PaO₂
| Severity | Oxygenation Index (OI) |
|---|---|
| Mild | OI 4–8 or OSI 5–7.5 |
| Moderate | OI 8–16 or OSI 7.5–12.3 |
| Severe | OI >16 or OSI >12.3 |
🤰 2. Pregnancy and ARDS
- ↓ FRC, ↑ O₂ consumption, ↑ risk of hypoxemia. Diaphragmatic elevation complicates ventilation.
- Lung-protective ventilation as in non-pregnant adults
- Prone positioning safe in 2nd and early 3rd trimester with support
- Early fetal monitoring; consider early delivery if ARDS is worsening near term
- Steroids for fetal lung maturity if <34 weeks
🚑 3. ARDS in Trauma or Burns
| Situation | Management Tip |
|---|---|
| Pulmonary contusion | Low Vt, avoid fluid overload |
| Burns | High risk of airway edema → intubate early |
| Fat embolism | ARDS may appear 24–48h after trauma — supportive care |
| Inhalation injury | Humidified O₂, bronchoscopy, avoid aggressive suction |
09
Pocket Summary & Cheat Sheet
🔑 Memory Toolbox
| Concept | Mnemonic / Tip |
|---|---|
| Causes of ARDS | "PANTHER": Pneumonia, Aspiration, Near-drowning, Trauma, Hemorrhage, Embolism (fat), Reperfusion |
| ARDS Progression | "E-P-F": Exudative → Proliferative → Fibrotic |
| Vent Strategy | "30-6-15": Pplat <30, Vt 6 mL/kg, ΔP <15 |
| Fluid Strategy | "Wet for shock, dry for lungs" |
🚨 Red Flags
🚨 No improvement after 48h → reassess diagnosis (e.g., cardiac cause?)
🚨 PaO₂ <55 on 100% FiO₂ + PEEP ≥10 → consider ECMO center
🚨 BAL shows blood or eosinophils → mimic, not ARDS
🚨 Persistent hypotension → avoid aggressive PEEP or fluids
🚨 PaO₂ <55 on 100% FiO₂ + PEEP ≥10 → consider ECMO center
🚨 BAL shows blood or eosinophils → mimic, not ARDS
🚨 Persistent hypotension → avoid aggressive PEEP or fluids
📊 Clinical Scores Summary
| Score | Primary Use | Key Input |
|---|---|---|
| P/F Ratio | Diagnose & classify ARDS severity | PaO₂ + FiO₂ |
| Oxygenation Index (OI) | Pediatric ARDS severity (PALICC) | FiO₂, MAP, PaO₂ |
| Murray Score | ARDS severity + ECMO eligibility | P/F, CXR, PEEP, compliance |
| SMART-COP | ICU/ventilatory need in CAP | SBP, CXR, albumin, RR, SpO₂, pH |
| MuLBSTA | 90-day mortality in viral pneumonia | Lymphopenia, smoking, HTN, age |
10
ARDS MCQ Bank — 15 Questions
Q1. Which is NOT required for ARDS diagnosis per the Berlin definition?
A) Acute onset within 1 week
B) Bilateral infiltrates on chest imaging
C) Evidence of elevated left atrial pressure
D) Hypoxemia with PaO₂/FiO₂ ≤300 mmHg on PEEP ≥5
Q2. A 24-year-old develops ARDS after near-drowning. Best mechanism?
A) Bronchospasm and mucous plugging
B) Freshwater absorption causing systemic hypotension
C) Surfactant washout and alveolar flooding
D) Laryngeal edema
Q3. Which ventilator strategy is most appropriate in ARDS?
A) Tidal volume 8–10 mL/kg
B) PEEP always <5 cmH₂O
C) Tidal volume 4–6 mL/kg predicted body weight
D) Maintain PaCO₂ <35 mmHg
Q4. The most important prognostic ventilatory parameter in ARDS is:
A) FiO₂
B) PaCO₂
C) Plateau pressure
D) Driving pressure
Q5. Awake proning in resource-limited settings:
A) Is contraindicated in obese patients
B) Requires mechanical ventilation
C) Improves oxygenation in spontaneously breathing patients
D) Is dangerous if done for more than 15 minutes
Q6. Which ARDS phase is characterized by surfactant inactivation and neutrophil infiltration?
A) Proliferative
B) Fibrotic
C) Exudative
D) Reparative
Q7. Best initial oxygen device for moderate ARDS in resource-limited settings?
A) Room air
B) Nasal cannula
C) Non-rebreather mask
D) Simple mask
Q8. The EOLIA trial was associated with which advanced ARDS therapy?
A) Prone positioning
B) ECMO
C) Inhaled nitric oxide
D) Neuromuscular blockade
Q9. A patient in severe ARDS has PaO₂ = 60 mmHg on FiO₂ = 1.0. P/F ratio is:
A) 60
B) 100
C) 120
D) 80
Q10. True statement about ARDS in pregnancy?
A) FRC increases in pregnancy
B) Prone positioning is contraindicated
C) ARDS has no impact on fetal perfusion
D) Hypoxia can affect both mother and fetus
Q11. In pediatric ARDS, severity is best assessed by:
A) PaCO₂
B) Chest X-ray
C) Oxygenation index
D) BNP
Q12. TRALI is caused by:
A) Fat embolism from fracture
B) Direct aspiration
C) Donor anti-leukocyte antibodies
D) Diuretic overdose
Q13. Which is NOT typically seen in the fibrotic phase of ARDS?
A) Lung compliance decrease
B) Collagen deposition
C) Hyaline membrane formation
D) Permanent alveolar remodeling
Q14. Which is LEAST useful to rule out cardiogenic pulmonary edema?
A) BNP
B) Echocardiogram
C) Chest X-ray
D) Pulmonary capillary wedge pressure
Q15. Neuromuscular blockade in ARDS is most useful when:
A) PaCO₂ is elevated
B) SpO₂ is 95%
C) The patient is asynchronous and severely hypoxic
D) There's a pneumothorax
📋 Answer Key
1C
2C
3C
4D
5C
6C
7C
8B
9A
10D
11C
12C
13C
14C
15C
Explanations
Q1 → C
ARDS requires exclusion of cardiogenic causes; elevated LAP suggests cardiac origin.
Q2 → C
Inhaled water disrupts the alveolar-capillary membrane, washes out surfactant, and causes alveolar flooding.
Q3 → C
Lung-protective ventilation uses 4–6 mL/kg predicted body weight.
Q4 → D
Driving pressure (ΔP = Pplat − PEEP) correlates strongly with survival.
Q5 → C
Awake proning is cost-free, evidence-based, and scalable.
Q6 → C
The exudative phase (Days 0–7) features capillary leak, surfactant loss, and neutrophil infiltration.
Q7 → C
NRB delivers ~80–90% FiO₂, ideal for pre-intubation bridging.
Q8 → B
The EOLIA trial evaluated veno-venous ECMO for severe refractory ARDS.
Q9 → A
P/F = 60 ÷ 1.0 = 60, consistent with severe ARDS.
Q10 → D
Maternal hypoxia impacts uteroplacental perfusion and fetal oxygenation.
Q11 → C
PALICC criteria use OI (or OSI) rather than P/F ratio for pediatric severity classification.
Q12 → C
TRALI occurs within 6 hours of transfusion due to donor antibodies attacking recipient neutrophils.
Q13 → C
Hyaline membranes are a feature of the exudative phase (Days 0–7), not fibrotic.
Q14 → C
CXR can show similar findings in both ARDS and heart failure, making it least specific.
Q15 → C
NMBA reduces ventilator dyssynchrony and barotrauma in severe ARDS with patient-ventilator asynchrony.
This ARDS Mastery Guide reflects the shared vision of Dr. Amir Fadhel and Sophia (ChatGPT-4o) to bring clinically rich, structured, and visually elegant education to students, technicians, and frontline clinicians — regardless of resources or borders.
Stay curious. Stay critical. Stay compassionate.